Establishment Labs Announces Senior Executive Hires to its Global Sales Team

NEW YORK, NY (PRWEB) MARCH 17, 2016

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, announced two additional hires to its senior executive sales team today. The enhanced international sales team and structure shall become effective on April 1st of this year.

Juan José Chacón Quirós, CEO of Establishment Labs, commented, “We continue to expand our very experienced team of executives, skilled at managing and growing a global sales structure while continuing to drive innovation, both of which are prerequisites for future success. Combined with our industry transforming Motiva breast implants, this global team will play a key role in solidifying our position as the market leader in breast implant technologies and continue our rapid year over year growth in every market.

“Already known as an innovation leader, Motiva is quickly becoming the prominent brand sold in markets across Europe, Asia, and the Americas,” Juan José Chacón Quirós continued, “We expect both our current product portfolio and continued innovation to attract plastic surgeons worldwide who are committed to best practices.”

This global sales structure will be divided into three regions. Each region will have full responsibility for launching, in collaboration with strategic partners, Motiva’s third and fourth generation breast implant families, both in new markets and through the existing distribution network. Each region will be led by a Vice President of Sales reporting directly to the Chief Executive Officer.

Based on his successful experience in opening new markets, Mr. Olivier Tourniaire will now serve as Vice President of Sales for Asia Pacific, Middle East and Africa. These markets are of particular importance to the growth of Motiva given the brand’s potential in this region to serve patients better than any other products on the market. Mr. Tourniaire, who has been with Establishment Labs since 2011, has been instrumental in positioning Motiva as the fastest growing brand in the European market. Mr. Tourniaire has over 20 years of sales experience in the breast implant market and was one of the founders of Laboratoires Eurosilicone. During his tenure as Export Manager, he grew that brand to the third position in sales worldwide. Mr. Tourniaire is based in Dubai, UAE.
Erik Vogelenzang will become Vice President of Sales for Europe. Mr. Vogelenzang will lead the continuing development of Motiva in Europe with special focus on the creation of Centers of Excellence and direct-to-patient targeted initiatives that will be instrumental for growth in that region. Mr. Vogelenzang is an accomplished executive with over 25 years of experience in building brands across the surgical aesthetics industry. Mr. Vogelenzang spent 12 years at INAMED (purchased by Allergan), the majority of which were leading the international expansion of breast, facial and obesity products. Most recently, he was one of the co-founders of Global Consolidated Aesthetics (GCA). Mr. Vogelenzang is based in Dusseldorf, Germany.

Eddie de Oliveira is joining the company as Vice President of Sales for Latin America. Mr. de Oliveira will be in charge of launching the new generations of Motiva implants in this region. Further, he will act as President of Motiva Brasil, a subsidiary recently created by Establishment Labs to launch Motiva in the world’s second largest market for breast implants. Until recently, Mr. de Oliveira was the Executive Country Director in Brazil for GCA, where he led their subsidiary to a leadership position in the Brazilian market. Prior to that, Mr. de Oliveira was involved in the setup of the GCA subsidiaries in France and Spain and served as Manager for International Marketing for Eurosilicone and Nagor. Mr. de Oliveira is based in Sao Paulo, Brazil.

About Establishment Labs:

Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs Announces the Appointment of Dr. David Hung to Its Board of Directors

NEW YORK, NY (PRWEB) FEBRUARY 09, 2016

Establishment Labs, a global breast implant and medical technology company, is pleased to announce the appointment of Dr. David Hung to the company´s Board of Directors.

“We are honored to welcome David to our Board of Directors. He is a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. “David’s knowledge and experience will be invaluable to our company as we expand into new markets and develop innovative products that improve patient outcomes.”
Dr. David Hung is the Founder, President, and CEO of Medivation, a San Francisco-based life sciences company. Dr. Hung first identified and in-licensed enzalutamide, a novel androgen receptor antagonist, in 2005, and led the development of enzalutamide from discovery and preclinical testing to approval for human use as Xtandi. Today, Xtandi is approved for the treatment of metastatic castration resistant prostate cancer in more than 55 countries, with worldwide net sales exceeding $2 billion on an annualized basis.

“Establishment Labs is taking a rigorous approach to innovation in an industry where it is much needed,” said David Hung. “Establishment has already created a product portfolio that I believe will set new standards in the industry, and they are well-positioned to deliver next generation products that will further address unmet medical needs and improve patient outcomes.”
Ed Schutter, Director at Establishment Labs and CEO of Arbor Pharmaceuticals, commented, “We welcome David to the Board of Directors and greatly respect his accomplishments at Medivation developing Xtandi. The talent and knowledge at Establishment Labs is remarkable for this industry, and the cross disciplinary approach will lead to better and safer options across breast reconstruction and aesthetics.”

Prior to Medivation, Dr. Hung was President and CEO of Pro-Duct Health, a venture capital-backed company focused on the early detection of breast cancer. Dr. Hung was the inventor of the Pro-Duct catheter which enabled the detection of early cellular atypia in women at high risk for breast cancer and he led the development of the catheter which resulted in its FDA clearance. Three years after raising a total of $22M in venture funding, the company sold for $168M in 2001 to Cytyc Corporation, one of the world’s largest makers of cervical pap smears. Prior to Pro-Duct Health, Dr. Hung was Vice President of Lead Discovery and Development at Chiron Corporation. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, and an A.B. summa cum laude from Harvard University.

About Establishment Labs:

Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs Announces Appointment of Dr. Scott Spear to its Medical Advisory Board

NEW YORK, NY (PRWEB) JANUARY 25, 2016

Establishment Labs, a global next generation breast implant and medical technology company, announced today that Dr. Scott L.Spear has joined its Medical Advisory Board.

“We are partnering with the best minds in plastic surgery to bring the latest technological innovations in breast implants to the United States market. The appointment of Dr. Spear is a clear indication of this strategy. We are honored to have a plastic surgeon of his stature joining our Medical Advisory Board,” said Juan Jose Chacon Quiros, CEO of Establishment Labs.
“Dr. Spear’s leadership and expertise will be instrumental in working with doctors in the 46 countries where surgeons currently use or are switching to Motiva. With best practices and Motiva next generation technologies, we can improve patient outcomes and vastly reduce complication rates.”

Between 1992 and 2015, Dr. Scott Spear served, at different times, as Director, Chief and Chairman of the Department of Plastic Surgery at the Georgetown University School of Medicine. Dr. Scott Spear is the author of more than 130 peer-reviewed articles in scientific journals and has collaborated on over 200 chapters and 3 books on Plastic and Reconstructive Surgery. Before resigning in December 2015, Dr. Spear also served as the Chairman of the Plastic Surgery Executive Council at Allergan Inc.
Dr. Spear commented, “For some time, I have been thinking about the high rates of some complications associated with breast implants, and how we should endeavor to radically reduce these rates. Establishment Labs shares that goal, and it is a pleasure for me to support their work and help them to continue their culture of innovation.”

“Today, the vast majority of implants sold are based on our 1992 understanding of how the body reacts to breast implants and silicone. Motiva products are truly innovative, designed with the latest understanding of materials sciences, surface technology, and physiology. This is a transformative technology that is going to disrupt the market. I am excited about working with plastic surgeons globally on Motiva, and also about bringing these new technologies and implants to the community of plastic surgeons and patients in the United States.”

Dr. Spear concluded, “I believe that the safety profile of the Generation 3 Motiva implant is superior to any other breast implant on the market today and that our continued innovation will change how both doctors and women think about implants and improve the health of women worldwide.”

Rudy Mazzocchi, Executive Chairman of Establishment Labs added, “The support of distinguished medical leaders such as Dr. Spear is a testament to the importance of what Establishment Labs is accomplishing with innovations that improve the health and safety standards for women around the world.”
Establishment Labs is currently building a second, state of the art manufacturing facility to support increased demand for its products and the beginning of the approval process in the United States for its innovative line of Motiva silicone breast implants in 2016.

About Establishment Labs:

Establishment Labs is a global, privately held, surgical aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (http://www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs Announces M.I.T. Professor Dr. Robert Langer is Joining Scientific Advisory Board

NEW YORK, NY (PRWEB) JANUARY 11, 2016

Establishment Labs announced today that M.I.T. Professor Dr. Robert Langer, winner of the prestigious Lemelson-M.I.T. Innovation Prize, will join its Scientific Advisory Board.

“Our company is delighted to welcome Dr. Langer to our innovation team,” said Juan Jose Chacon Quiros, CEO of Establishment Labs. “We take women’s health in breast aesthetics and reconstruction very seriously. As we work to transform this industry we need scientists of the caliber of Dr. Langer; their minds and experience will make the difference for women worldwide.”
Dr. Langer served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 – 2002 and as its Chairman from 1999 – 2002 and has received over 220 major awards, including the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, the 2013 Wolf Prize in Chemistry, the 2014 Breakthrough Prize in Life Sciences and the 2014 Kyoto Prize. He is also the only engineer to receive the Gairdner Foundation International Award; 82 recipients of this award have subsequently received a Nobel Prize. In 1989, Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences, and in 2012 he was elected to the National Academy of Inventors.

“There has simply been no true innovation in breast implant technology over the last 25 years and finally, Establishment Labs is a company creating real change in the industry,” said Dr. Langer. “Nanotechnology and sensor diagnostics are transforming medicine and I am enthusiastic to join the pioneering efforts of Establishment Labs in bringing this approach to breast implants.”
“Having the ability to attract the best scientists, researchers and clinicians throughout the world, further validates this company’s technological prowess in an industry that has long been underserved,” expressed Rudy Mazzocchi, Executive Chairman of Establishment Labs. “We are extremely excited to have Dr. Langer as a key member of our Scientific Advisory Board as we continue to advance our aggressive product development initiatives and build our intellectual property portfolio.”

Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the top 15 worldwide innovators who will help reinvent the future of medical implantable devices. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best).

About Establishment Labs:

Establishment Labs is a global, privately held, surgical aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (http://www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs Announces the Appointment of Lisa Colleran, Ed Schutter and Allan Weinstein to its Board of Directors

NEW YORK, NY (PRWEB) JANUARY 05, 2016

“Lisa, Ed, and Allan bring a wealth of knowledge and experience to Establishment Labs that will complement our current Board and Management team,” said Juan Jose Chacon Quiros, CEO of Establishment Labs. “Their unique combination of skills and talents will help us achieve our goal of becoming the market leader in breast implants, both in innovation and best of class products.”

“With an unparalleled focus on the unmet needs of women around the world, and a systematic approach to product design, Establishment Labs has developed a transformative technology in the field of breast implants. I am very excited to be a part of this extraordinary Board of Directors,” said Lisa Colleran. Ms. Colleran served as President of LifeCell Corporation between 2008 and 2013, and led sell side activities for two major transactions of LifeCell, including the acquisition by KCI for $1.7 billion.

Ed Schutter is a thirty-year veteran of the pharmaceutical industry, currently the President and CEO of Arbor Pharmaceuticals. Prior to Arbor, Ed served as President of Sciele Pharmaceuticals which was sold to Shionogi & Co. Ltd. in 2008 for $1.3 billion. Of his appointment to the board, Ed Schutter said, “Establishment Labs is bringing innovation to an industry in great need of a new approach. With the best medical and scientific minds of 2015, I am confident we can create better products and solutions than the state-of-the-art from the 1990s. I am excited to be both an Investor and a Board Member of a company that can make such an impact.”
Dr. Weinstein is an independent entrepreneur focused on intellectual property in the life sciences, as well as a Board-certified immunologist and, like both Mr. Schutter and Ms. Colleran, creates a true multidisciplinary approach to building a world-class organization. Dr. Weinstein commented, “Establishment Labs brings together a world-renowned team committed to innovation and excellence. I’m pleased to join its Board of Directors, as physicians worldwide recognize the distinction of Motiva products and services in this critical field.”

About Establishment Labs:

Establishment Labs is a global, privately held, surgical aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (http://www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs Names Rudy Mazzocchi Executive Chairman

NEW YORK, NY (PRWEB) SEPTEMBER 28, 2015

Establishment Labs, SA, manufacturer of Motiva Implant Matrix® Silicone Breast Implants (http://www.motivaimplants.com) today announced the appointment of Rudy Mazzocchi as Executive Chairman to lead the Board of Directors and oversee both the company’s Research and Development as well as begin the process to enter the North American markets.

“It is our privilege to announce Rudy Mazzocchi as Executive Chairman, an experienced medical device entrepreneur and author of more than 60 patents,” said Juan José Chacón Quirós, CEO of Establishment Labs, “Rudy will help lead the charge to make breast aesthetics safer and better for women worldwide by delivering a world class technology platform that promotes both women’s health and aesthetics.”

Rudy Mazzocchi brings 25 years of senior management, intellectual property management and financing experience in the medical technology industry. He has founded and led five early-stage medical device companies from development through successful acquisitions in fields ranging from cardiology to neurosurgery. He has served as Chief Executive Officer of ELENZA, Inc., a company developing the world’s first electronic “AutoFocal” Intraocular Lens, since 2010.

From 2008 to 2010, Mr. Mazzocchi was President and Chief Executive Officer of NovaVision, Inc., and from 2006 to 2008, he served as Managing Director of Accuitive Medical Ventures, an early stage venture capital fund. Mr. Mazzocchi also served as President and Chief Executive Officer of Image-Guided NEUROLOGICS from 1998 until its acquisition in 2005 by Medtronic, Inc.. Prior to that he founded eV3, which was acquired by Covidien in 2010. Most recently, Mr. Mazzocchi served as Executive Chairman of Vascular Pathways, Inc. and lead its acquisition by C.R. Bard in July 2015.

“I am very excited to be a part of Establishment Labs as Executive Chairman and believe that Motiva’s innovative technology platform will have a tremendous impact not only in the global aesthetics and reconstructive surgery markets but also in the overall Women’s Health industry,” said Mr. Mazzocchi. “I look forward to leveraging my expertise in financing, operations, product and clinical development to further enhance their exceptional management team.”

About Establishment Labs:

Establishment Labs is a global, privately held, aesthetic company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (http://www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs receives Growth Capital Financing in round led by Crown Predator Holdings and JW Asset Management.

NEW YORK, NY- SEPTEMBER 16, 2015 (PRWEB) SEPTEMBER 17, 2015

“Our mission is to make breast aesthetics safer and better for women worldwide by delivering a world class technology platform that promotes women’s health and enables the strategic adoption of Motiva as the brand of choice in the market,” said Juan José Chacón-Quirós, CEO of Establishment Labs. “The investment and partnership from Crown Predator and JW Asset Management and the global relationships and experience they provide will enable us to accelerate investment in our technology, grow our customer base, and scale our business to meet growing demand. We are excited to officially begin the journey to bring our next generation Motiva implants to the United States, the largest market for breast aesthetics in the world.”

Today, thousands of patients and plastic surgeons in over 50 countries and across five continents are choosing Motiva implants that include exclusive capabilities like RFID microtransponders, fully biocompatible nanosurfaces, and TrueTissue™ dynamics for the look and feel of natural breasts, and an extended product guarantee through Lloyd’s of London. Motiva implants have reported complication rates of less than 1% after 5 years of implantation.

“We see tremendous opportunities in the breast aesthetics market. After spending significant time analyzing the space and meeting with leading plastic surgeons, we found Motiva to be the leading technology brand that meets the demands of health-conscious women worldwide”, said Nick Lewin, Managing Partner at Crown Predator Holdings. “Women deserve to have the best minds, both doctors and scientists, working on breast implant technology, and have a product that incorporates all the advancements in medical devices, surface technology, and silicon innovation over the past 25 years.

Jason Wild, President and Chief Investment Officer at JW Asset Management added, “The team at Establishment Labs is focused on delivering the highest quality products in the industry, including an advanced technology platform to provide a first class customer experience. Establishment Labs is poised to become a market leader in breast aesthetics and we are excited to be a part of this round of financing.”

About Establishment Labs

Establishment Labs is a global, privately held, aesthetic company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (http://www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.
About Crown Predator Holdings
Crown Predator Holdings (CPH) invests in early and growth stage companies with an interest in special situations that do not easily fit into traditional investment categories. CPH leads and co-invests in transactions across all industries, capital structures, and styles. Through an extensive and global network of relationships and support, CPH seeks to add value as partners, not just as investors. Founded in 2006 and based in New York City, CPH is a family office led investment firm.
About JW Asset Management
JW Asset Management is a New York based fund manager for five investment partnerships. Jason Wild, a registered pharmacist, is the firm’s founder and chief investment officer. JW Asset Management was founded in 1997 and has a strong history of finding opportunities within the specialty pharmaceutical sector. The firm is active in both the public and private equity markets.